TEVA · Teva announced it will discontinue the Phase 2 TOPAS-MSA study of…

Teva announced it will discontinue the Phase 2 TOPAS-MSA study of emrusolmin (TEV-286) for multiple system atrophy (MSA) after a pre-specified interim futility analysis met the criterion, indicating a low probability of meeting the primary endpoint. No safety concerns were identified. The decision is a setback for Teva's neuroscience pipeline, though the company stated it does not represent a final decision on the broader emrusolmin program and will analyze open-label extension data.

• Phase 2 TOPAS-MSA study (NCT06568237) evaluating emrusolmin in MSA is discontinued after interim futility analysis met predefined criterion
• Interim analysis indicated low probability of study meeting primary efficacy endpoint if continued
• No safety concerns were identified in the interim analysis
• Emrusolmin is being developed in partnership with MODAG GmbH